FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Medicure's Free Cash Flow for the
three
months ended in Mar. 2026 was €-1.15 Mil. Medicure's Revenue for the
three
months ended in Mar. 2026 was €5.01 Mil. Therefore, Medicure's FCF Margin % for the quarter that ended in Mar. 2026 was -22.97%.
The historical rank and industry rank for Medicure's FCF Margin % or its related term are showing as below:
STU:NGQ1'
s FCF Margin % Range Over the Past 10 Years
Min: -141.21 Med: 4.75 Max: 75.93
Current: -9.78
During the past 13 years, the highest FCF Margin % of Medicure was 75.93%. The lowest was -141.21%. And the median was 4.75%.
STU:NGQ1's FCF Margin % is ranked worse than 73.18% of 962
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs STU:NGQ1: -9.78
Medicure FCF Margin % Related Terms
Medicure FCF Margin % Historical Data
* Premium members only.
The historical data trend for Medicure's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medicure's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicure FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicure's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Medicure's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicure (STU:NGQ1) has a FCF Margin % of -22.97% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Medicure and its competitors. According to the industry distribution chart, Medicure ranks #704 out of 962 companies in the Drug Manufacturers industry, placing it in the top 73.2%.
Is Medicure's FCF Margin % too high?
Medicure's current FCF Margin % is -22.97%. Based on the distribution chart, Medicure ranks #704 out of 962 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Medicure has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Medicure's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medicure ranks #704 out of 962 companies for FCF Margin %. This places Medicure in the lower half of its industry. The industry median FCF Margin % is 2.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Medicure and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicure's current FCF Margin % is -22.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicure stock overvalued right now?
Medicure (STU:NGQ1) has a current FCF Margin % of -22.97%. The stock's GF Value™ is €0.76, compared to a current price of €0.63 — trading 17.8% below its estimated fair value. The current FCF Margin % is -22.97%. Medicure's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Medicure (STU:NGQ1), the current FCF Margin % is -22.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicure (STU:NGQ1) Overvalued in 2026?
Based on GuruFocus' analysis, Medicure stock appears to be undervalued.
The current stock price of €0.63 is trading 17.8% below its estimated GF Value™ of €0.76.
Key valuation signals for STU:NGQ1:
FCF Margin %: -22.97%
GF Value™: €0.76 vs. price of €0.63 (17.8% below fair value)
No single metric tells the full story. See the STU:NGQ1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicure Inc is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market and sales to the Retail Public of pharmaceutical products. The Company's present focus is the sale and marketing of its cardiovascular products, AGGRASTAT, ZYPITAMAG, and increasing its e-commerce and mail order pharmaceutical business. The Company operates under two segments: the marketing and distribution of commercial products and the operation of a retail and mail order pharmacy. It generates the majority of its revenue from the Retail and Mail Order Pharmacy segment.
62GF Score
Get the complete analysis for STU:NGQ1
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:NGQ1 has been successfully added to your 
